

NEWSLETTER

**Hong Kong Association of Critical
Care Nurses Limited (HKACCN)**

Message from the President

Vol. 24, No. 1, Nov 2023

LEUNG Fung Yee
President
HKACCN



Dear Members of the Critical Care Nurses Association,

I hope this message finds you all in good health and high spirits as we continue to navigate the challenges of our profession. Global pandemic in the past three years has tested our resilience like never before. We have witnessed the devastating impact of COVID-19, and our intensive care units have been on the front line of this battle. Despite the difficulties, you have risen to the occasion, demonstrating extra-ordinary courage and compassion in the face of adversity. Your tireless efforts have saved countless lives, and I am immensely proud to lead an association comprised of such remarkable critical care nurses in Hong Kong.

Since the healthcare landscape continues to evolve rapidly, we must stay at the forefront of innovation and best practices to deliver the highest standard of care. As critical care nurses, we shoulder the responsibility of advocating for our patients and ensuring their well-being during their most vulnerable moments. Let us continue to embrace lifelong learning and professional development, empowering ourselves with the knowledge and



necessary skills to meet the evolving needs of our patients.

Yet, collaboration and camaraderie are the core value of our association. Our collective strength lies in our ability to come together, share experiences, and support one another. I encourage you all to actively engage in the various educational and networking opportunities provided by our association. Together, we can foster an environment of growth and mutual support that elevates our profession to new heights.

This year, according to the constitution of our association, we have conducted an election for a new Board of Directors for the term 2023-2025. As we are going to embark on a new chapter, I would like to express my gratitude to the outgoing Board Members for their remarkable contributions and unwavering commitment during the past 2 years. Their selfless dedication to our Association during the difficult time of COVID-19 outbreak are instrumental in ensuring the success of our association.

Now, I would like to extend my warmest congratulations and a heartfelt welcome to the newly elected Board of Directors (please refer to the table). In this term, we are thrilled to have a large group of enthusiastic members with diverse backgrounds and experiences to join our new board for continuing development of our association. I am very honoured to serve as the President again, and I am humbled by the privilege of leading such an exceptional group of critical care nurses. Together, let us continue to champion the highest standard of care, advocate for our patients, and support each other on this remarkable journey.



PHILIPS

Patient monitoring

IntelliVue Information
Center iX

See the **big picture** – where and when you need it

Philips IntelliVue Information Center iX

High acuity patient care is challenging and complex. Your patient monitoring solution should provide you with what you need to meet this challenge. The Philips IntelliVue Information Center (PIIC iX) is a powerful, real-time patient monitoring solution that consolidates rich, detailed, physiological data from patient monitors and clinical information systems and provides this data to you from virtually anywhere at any time – even sending data and waveforms to your mobile device. With on-demand access to patient monitoring data – both near real-time and historical views – it supports your needs in today's on-the-move world.

PIIC iX allows you to track your patients' data as they move through the hospital, from the Emergency Department to the Operating Room to the ICU and Progressive Care Units. PIIC iX supports standard IT practices and works with your existing hospital IT infrastructure, communicating with your EMR, ADT, and lab systems so you have access to data to help you treat patients and provide quality care.

Key advantages

- Provides a clear view of patient condition
- Aids clinical collaboration and review of patient data from virtually anywhere
- Offers access to historical patient data for research through an SQL database
- Can provide access to vital signs data with a single click from the patient's EMR
- Provides clinical decision support tools including ST Limit Maps, clinical application suites and alarm management
- Facilitates a continuous patient record

HKACCN Board of Directors 2023 - 2025	
President	Ms. LEUNG Fung Yee
Vice President	Ms. Vivien LAI
Secretaries	Ms. CHAN Yuk Ching (1st) Mr. CHAN Yui Fung, Alex (2nd)
Treasurers	Ms. LI Yuen (1st) Ms. Everlyn CHAM (2nd)
Broad Members	Ms. LAU Ting Ming Ms. Ruby TSE Ms. Peggy WONG Ms. WONG Pui Shan Ms. WONG Wing Yan Mr. Timothy WU Ms. YEUNG Mui Fong Mr. Ross YAU Mr. Wayne YU
Advisors	Ms. MAK Wai Ling Mr. LUK Hing Wah Mr. Paul WONG
Chief Editor	Dr. Vico CHIANG
Co-opted Members	Mr. AU YEUNG Chun Ho Ms. CHEUNG Wai Ki Ms. Carol KU Ms. KWOK Siu Yan Mr. LO Chun Yee Ms. Connie NG Mr. TANG Lung Kwan



Evidence-based Practice: The Impact of Early Mobilization Program on Critically Ill Patients in Intensive Care Unit

Lau Ka Lam, APN
Intensive Care Unit
Tseung Kwan O Hospital

Introduction

In the challenging landscape of intensive care units (ICUs), optimizing patient recovery and outcomes remains a paramount goal. One of the most significant obstacles to patient recovery is ICU-acquired weakness (ICU-AW). It greatly affects a substantial number of critically ill patients (Alaparthy, Gatty, Samuel, & Amaravadi, 2020; Cameron et al., 2015; Hill, 2022; Wang et al., 2020). ICU-AW leads to muscle atrophy, decreased mobility

, and various complications (Alaparthy et al., 2020; Wang et al., 2020). To prevent these issues, early mobilization program (EMP) has gained recognition to enhance patient muscle recovery. It reduces ICU-AW as well as the related complications (Alaparthy et al., 2020; Schallom et al., 2020; Wang et al., 2020). Despite the recognized benefits of EMP for critically ill patients, there is a lack of extensive studies and clear guidelines for its implementation (Nydahl et al., 2018). Challenges to implement EMP including low compliance and safety concerns among staff, which have hindered the widespread adoption of EMP in critical care settings (Cameron et al., 2015; deSouza et al., 2022). This summary reports the findings of a recent study that investigated the impact of EMP on critically ill patients in a local ICU.

Objectives

The objective of this study is to investigate the effects of EMP on ICU patient's mobility; and secondarily to enhance ICU nurse's competency to promote EMP.

Methods

The data were collected from an adult ICU in Tseung Kwan O Hospital over an 11-month period (July 1, 2022 to May 31, 2023) through convenience sampling. To ensure systematic implementation of EMP, our team developed a flow chart and instruction sheet to provide guidance to the nurses in ICU. Patient assessments were conducted twice daily by intensive care nurses commencing 24 hours after admission to ICU. The assessments included vital parameters by the scores of Richmond Agitation-Sedation Scale (RASS) and Glasgow Coma Scale (GCS), and muscle strength. These data were used to determine each patient's specific ICU mobility, referencing the provided EMP flow chart.

Under the EMP framework, participating nurses provided mobilization exercises, which were tailored to each patient's mobility scale. The spectrum of activities ranged from minimal intervention (passive exercises at the bedside) to more extensive effort of the patient (bedside marching — performing over four or more steps). Each EMP session was designed to last

for a minimum of 15 minutes, and each EMP session was documented in the designated data collection sheet.

Statistical Package for the Social Sciences (SPSS) was used for data analysis. The compliance rate and demographic information of participating patients were summarized using frequencies and percentages. Wilcoxon signed-rank test was used to assess the differences in muscle strength and mobility scores before (Pre-EMP) and after (Post-EMP) patients participated in the EMP, particularly upon their discharge from the ICU.

Results

A total of 114 participants were included for analysis after excluding 142 cases deemed ineligible due to their physical or psychological in-stability. These 114 patients are comprised of 68 males and 46 females from various specialties (62.3% medical, 28.1% surgical, and the rest in other fields). The compliance rate for implementing EMP exceeded expectations, reaching an impressive 82%. This noteworthy level of compliance suggests

the feasibility of implementing EMP for ICU patients as perceived by healthcare professionals.

The study also unveiled significant enhancement in patient mobility ($p < .001$), specifically in terms of upper limb strength (pre-EMP mean: 3.63; post-EMP mean: 4.56), lower limb strength (pre-EMP mean: 3.38; post-EMP mean: 4.24), and mobility score (pre-EMP mean: 1.38; post-EMP mean: 3.31) following the implementation of EMP. The improvement in mobility suggests that EMP holds promise for enhancing the physical well-being and functional outcomes of ICU patients.

Limitations

Limitations of this study include a potential selection bias and the absence of a control group. To address these limitations and provide better understanding of the impact of EMP, it is suggested to have randomized controlled trials in diverse patient populations.

Conclusion

This study highlights the potential benefits



宏康醫療有限公司
Success Medical Company Limited

Tel: (852) 2420 2983

Fax: (852) 2420 3983

www.successmedical.com.hk

Specialized in Emergency & First Aid Equipment

專營急救器材及訓練模型

SAM
MEDICAL

Nasco
HEALTHCARE

VBM

 **BT Inc.**
BEST TECHNOLOGY & BETTER TOMORROW

 **Rescuer**
BLS
BLS Systems Limited

Armstrong
Medical
INDUSTRIES INC.

GCE
Gas Control Equipment

 **SunMed**


Therapy
Equipment Ltd

of EMPs in ICU settings, emphasizing its positive impact on muscle strength and mobility. With the encouraging results from this study, our team hopes to inspire further research and discussion on this issue, aiming at advancing ICU patient recovery and outcomes.

References

Alaparthy, G.K., Gatty, A., Samuel, S.R., & Amaravadi, S.K. (2020). Effectiveness, safety, and barriers to early mobilization in the intensive care unit. *Critical Care Research and Practice*, 2020(6), 1-14. doi: 10.1155/2020/7840743

Cameron, S., Ball, I., Cepinskas, G., Choong, K., Doherty, T.J., Ellis, C.G., Martin, C.M., Mele, T.S., Sharpe, M., Shoemaker, J.K., & Fraser, D.D. (2015). Early mobilization in the critical care unit: A review of adult and pediatric literature. *Journal of Critical Care*, 30(4), 664-672. doi: 10.1016/j.jccr.2015.03.032

de Souza, P.N., Kroth, J.B., dos Santos Ligerio, A., Mendes, J.M., Maida, A.L.V., Pastore, L., & Yamaguti, W.P. (2022). Effectiveness of a quality improvement strategy with implementation of a specific visual tool to promote ICU early mobilization. *Scientific Report*, 12(1), 17206. doi: 10.1038/s41598-022-21227-y

Hill, L.A. (2022). *Nurse-led intervention: Implementing early mobilization of patients in the intensive care unit*. Retrieved from <https://soar.usa.edu/cgi/viewcontent.cgi?article=1093&context=scholprojects>

Nydahl, P., Gunther, U., Diers, A., Hesse, S., Kerschensteiner, C., Klarmann, S., Borzikowsky, C., & Kopke, S. (2018). PROtocol-based MObilizaTION on intensive care units: Stepped-wedge, cluster-randomized pilot study (Pro-Motion). *Nursing in Critical Care*, 25(6), 368-375. doi: 10.1111

/ncc.12438

Schallom, M., Tymkew, H., Vyers, K., Prentice, D., Sona, C., Norris, T., & Arroyo, C. (2020). Implementation of an inter-disciplinary AACN early mobility protocol. *Critical Care Nurse*, 40(4), e7-17. doi: 10.4037/ccn2020632

Wang, J., Ren, D., Liu, Y., Wang, Y., Zhang, B., & Xiao, Q. (2020). Effects of early mobilization on the prognosis of critically ill patients: A systematic review and meta-analysis. *International Journal of Nursing Studies*, 110(103708),1-7. doi: 10.1016/j.ijnurstu.2020.103708

Embracing the Challenges in Pain Management: Strategies for Optimal Patient Outcomes

Wong Ching Kwan, RN
Tang Chi Chung, RN
Intensive Care Unit
Tuen Mun Hospital

Pain is regarded as the fifth vital sign but is often overlooked (Morone & Weiner, 2013). In the Intensive Care Unit (ICU), effective pain management that includes pharmacological and non-pharmacological interventions could re-

We Serve,
We Care!



嘉榮醫療有限公司®
GOODWIN health care ltd.



Goodwin Health Care Ltd.
Tel: (852) 2408 8838
Fax: (852) 2408 1329
Email: hksales@goodwin.com.hk
Website: www.goodwin.com.hk



duce the incidence and severity of delirium and promote patient recovery (Pisani et al., 2019). To empower ICU nurses in pain management and enhance the nursing care of patients with IV-Patient Controlled Analgesia (PCA), a PCA Fentanyl User Guide was developed and implemented in the ICU of Tuen Mun Hospital. A pilot program on non-pharmacological pain management was also launched.

The PCA Fentanyl User Guide: Empowering Junior Nurses

Patient Controlled Analgesia (PCA) has proven to be more effective at pain control than non-patient-controlled opioid injections and resulted in higher patient satisfaction (McNicol et al., 2015). The comprehensive PCA Fentanyl User Guide outlines standardized nursing roles, points for patient education with the '6Ws' framework (Fig. 1), and instructions for handling PCA machines during different phases of IV PCA management.

The user guide incorporates the mnemonic "OPIOID", which ensures that critical steps are not overlooked during PCA initiation, administration, observation, and termination (Fig. 2). By implementing this user guide, patient safety in the ICU is promoted, nurse competence enhanced, patient education empowered, and effective pain relief facilitated. Additional in-house training for junior nurses based on the Guide enhances its implementation and fosters a culture of standardized practice.




Fig. 2 The Mnemonic OPIOID

ICU Pain Team IV PCA Manual

Points for Patient Education



What is the purpose or function of IV PCA?

1. Explain that PCA allows patients to self-administer pain medication.
2. Emphasize that PCA helps in achieving better pain control, faster pain relief, and promotes early mobilization.

WHY

Why is PCA beneficial on pain management?

1. Describe how PCA can provide personalized pain management tailored to the patient's PCA empowers patients to have more control over their pain relief.

What

When

How

When should patients consider using PCA for pain relief?

- How to use IV PCA machine**
1. Introduce the concept of lock-out time, which prevents the patient from administering additional doses too close together.
 2. Explain the 1-hour limit, which ensures that the patient does not exceed a certain amount of medication within a given timeframe.

1. Instruct patients to use PCA when they start feeling pain.
2. Advise patients to use PCA before engaging in activities that may cause pain.
3. Emphasize the importance of using PCA before breathing and coughing exercises or before moving or turning.

Who

Who can operate PCA machine

Inform patients that only they are allowed to press the demand button on the PCA device. Emphasize the importance of not allowing anyone else to use the PCA system.

Where

Where do the opioid react ?

Describe that PCA delivers medication intravenously to ensure a quick and effective pain relief. Explain that the medication is delivered directly into the bloodstream through an IV line

Fig. 1 Points for Patient Education with the '6Ws' Framework

A Successful Experience: Non-Pharmacological Pain Management Program

A successful 8-week pilot program focused on non-pharmacological pain management has also been implemented in the ICU for patients. This program introduces interventions such as aromatherapy, cold therapy, music listening, and deep breathing exercises, which can reduce significant pain among critical patients (Kia et al., 2021). Over 90% of the participants have reported the effectiveness of these interventions. Clear guidelines, education, and established workflows have been provided to ensure staff compliance. This holistic approach addresses the psychological and emotional aspects of pain, improving patient comfort and reducing reliance on opioids. The program's achievement establishes a foundation for integrating non-pharmacological interventions as standard practice in ICU pain management, optimizing patient care.


Conclusion

A comprehensive approach to pain

management that effectively addresses the challenges faced in providing optimal care to patients has been implemented in the ICU of Tuen Mun Hospital. Implementing a PCA Fentanyl User Guide has empowered nurses to deliver standardized and competent pain management. The success of the Non-Pharmacological Pain Management Program highlights the efficacy of alternative interventions such as aromatherapy, cold therapy, music listening, and deep breathing exercises. Creating a soothing ICU environment enhances patient comfort and improves overall healing. Tuen Mun Hospital is committed to optimizing pain management and improving patient outcomes within the ICU setting through these initiatives.

References

Kia, Z., Allahbakhshian, M., Ilkhani, M., Nasiri, M., & Allahbakhshian, A. (2021). Nurses' use of non-pharmacological pain management methods in intensive care units: A descriptive cross-sectional study. *Complementary Therapies in Medicine*, 58, 102705.



Enlight 2100
(EIT Pulmonary Monitor)

Multicare X offers Automatic Lateral Platform Tilting (ALT) to help open patient's lung by changing its mechanics in a safe way, while Enlight 2100 enables a real-time dynamic EIT imaging to guide the process in order to achieve safe ventilation.

MULTICARE X Bed with Enlight 2100


☎ 2487 7077
✉ inquiry@janley.com.hk

 晉利有限公司
JANLEY LIMITED



**FRESENIUS
KABI**

caring for life



Supportan® DRINK

Quality of Life support in oncology

1.5 kcal/ml, high protein oral nutritional supplement for the dietary management of patients with or at risk of malnutrition, in particular those with cancer, chronic catabolic disease or cachexia

Recommended 2 bottles per day

Provides 2 g eicosapentaenoic acid (EPA) per day

✓ to counteract muscle wasting and support immune function

High in protein (27 energy %)

✓ to compensate for an increased protein turnover and counteract loss of muscle mass

Increased content of fat (40 energy %)

✓ adapted to the specific metabolic changes in cancer patients with fat being the preferred energy substrate

High energy density (1.5 kcal/ml)

✓ to ensure a tolerable volume and high long-term compliance

Choice of 3 delicious flavours

✓ taste of Supportan sip feed rated superior in blind taste tests against similar sip feeds*

* blind taste tests were conducted by an independent institute for sensorial analysis against similar products for cancer patients (sip feeds, high in EPA)



www.fresubin.com/hk



Enquiry: (852) 2176 1912



Fresenius Kabi Hong Kong Ltd. Room 5001-5016, 50/F, Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong
Tel: (852) 2152 1330 Fax: (852) 2119 0815 Email: infohk@fresenius-kabi.com www.fresenius-kabi.com/hk

- McNicol, E. D., Ferguson, M. C., & Hudcova, J. (2015). Patient controlled opioid analgesia versus non-patient controlled opioid analgesia for postoperative pain. *Cochrane Database of Systematic Reviews*, 2015(6), CD003348. doi:10.1002/14651858.CD003348.pub3
- Morone, N. E., & Weiner, D. K. (2013). Pain as the fifth vital sign: exposing the vital need for pain education. *Clinical Therapeutics*, 35(11), 1728-1732.
- Pisani, M. A., Devlin, J. W., & Skrobik, Y. (2019). Pain and delirium in critical illness: An exploration of key 2018 SCCM PADIS guideline evidence gaps. *Seminars in Respiratory and Critical Care Medicine*, 40(05), 604-613.

Use of Anaesthetic Conserving Device for Refractory Status Epilepticus in ICU

Paul Wong, ANC
 Ruby Wong, NC
 Intensive Care Unit
 Queen Elizabeth Hospital

Background

The Neurocritical Care Society defines status epilepticus (SE) as a life-threatening neurologic condition, that lasts for 5 or more minutes of either continuous seizure activity or repetitive seizures without regaining consciousness (Brophy et al., 2012). It is a life-threatening condition causing different significant morbidity & mortality, including cerebral hypoxia, respiratory arrest, rhabdomyolysis and cardiac arrhythmia.

Treatment for SE includes the use of benzodiazepines, intravenous anti-epileptic drugs and intravenous anaesthetic agents that suppress or terminate abnormal cerebral electrical activities. However, 20% of the patients will develop refractory SE, which is the New Onset Super-Refractory Status Epilepticus (NOSRSE), a term firstly used by Wilder-Smith et al. (2005). Patients with NOSRSE have persistent SE for more than 24 hours despite the use of intravenous anti-epileptic drugs, benzodiazepines, and anaesthetic agents. The mortality rate of these patients can be up to 30% in adults with significant long-term neurological sequelae, only around 27 - 50% of them could have a definite cause being identified, including autoimmune encephalitis, infections, neoplasm, and gene mutation (Stavropoulos, Khaw & Valentin, 2023).

Current ICU sedation practice predominantly relies on benzodiazepines, which are commonly combined with opioids to provide analgesia and co-sedation to control SE. Prolonged use of the

benzodiazepines, anti-epileptic drugs, and intravenous anaesthetic agents in attempts to control NOSRSE causes withdrawal, liver intoxication, renal impairment, hemodynamic instability and prolonged weaning.

Introduction of Volatile Anaesthetic Agent in ICU

For patients with status epilepticus, status asthmaticus, and addiction withdrawal syndrome, the use of volatile anaesthetic agent (VAA) to replace intravenous anaesthetic agent increased dramatically in the US and Europe during the COVID-19 pandemic due to the inadequate supply of intravenous anaesthetic agents. For decades, VAA has been used for major surgery based on the delivery of volatile anaesthetics such as nitrous oxide, isoflurane, desflurane, or sevoflurane for inhalation to produce general anaesthesia. It is achieved by preventing pre-synaptic excitation, blocking post synaptic neurotransmitter, and enhancing GABA and glycine that promote relaxation and sleep (Fig. 1). The benefits of VAA include rapid onset, lower dose and easy to titrate. VAA can produce bronchodilation and anti-convulsion effects, as well as improving regional blood flow to the heart, liver, kidneys, and brain.




Fig. 1 Mechanism of the Action of Volatile Anaesthetic Agent (VAA) (modified from Jerath et al., 2016)

Although the benefits of VAA are obvious and superior to intravenous anaesthetics, it requires special cartilage and cassette of VAA to administer through vaporizers of the anaesthetic machine. The set of equipment is bulky, difficult to access, and unable to be connected to modern ICU ventilators; and not all staff are trained to use. This hinders the use of VAA in ICU.

Application of Anaesthetic Conserving Device in ICU

In recent years, the development of Anaesthetic Conserving Device (ACD) (Fig. 2) favours the



Servo-c Ventilator

Introducing the new Servo for personalized ventilation

It's here! With your evolving needs for safe, high-quality ventilation and usability in mind, we're proud to introduce Getinge Servo-c, our next-generation ventilator for pediatrics and adults. Designed from the ground up to meet the needs of tomorrow and comply with the latest requirements for acuity care, it is a natural evolution of 50 years of refined and improved Servo performance.




Servo-u Ventilator

Personalized lung protection breath by breath

Exercise the diaphragm and protect the lungs


NAVA (Neurally Adjusted Ventilatory Assist) follows the patient's Edi to personalize lung-protective spontaneous breathing with higher diaphragmatic efficiency, and fewer periods of over- and under-assist. It may improve the patient's ICU experience, helping to reduce sedation with improved comfort and sleep quality. NAVA shortens the time of weaning and mechanical ventilation and increases the number of ventilator-free days.

NIV NAVA significantly improves patient-ventilator interaction, and reduces NIV complications. For patients with acute exacerbation of COPD it can be effective in managing their status and to improve patient outcomes.



Transpulmonary pressure

To simplify esophageal manometry and improve accuracy, we have developed an automatic maneuver to validate balloon positioning and filling. A diagnostic view provides esophageal (Pes) and transpulmonary (PL) pressure waveforms, with key parameters for safe assessment of controlled and spontaneous ventilation. The relationship between airway and transpulmonary pressures is now much more intuitive.



Fast and reliable CO₂ monitoring

To measure carbon dioxide levels in real time during expiration (capnography), Servo comes with an easy-to-use CO₂ monitoring option. It helps you to improve the ventilation quality and efficiency for your patients. In other words, yet another tool on Servo to help you personalize your treatments.

This document is intended to provide information to an international audience outside of the US.

Cardiohelp System

The world's leading ECLS System

The Cardiohelp System is a compact cardiopulmonary support system suitable for a wide range of indications in intensive care, emergency medicine, cardiology, and cardiac surgery.

Highly portable, the Cardiohelp System can be rapidly deployed to transport patients within and between hospitals, requiring respiratory and / or circulatory support.



Rotaflow II System

Proven strength. Reinvented.

The Rotaflow II Centrifugal Pump System is at your side, with a lighter and compact unit for easier transport.

The improved user interface, with familiar elements, is easy-to-use and intuitive to operate.



Maquet Moduevo Intensive Care and Recovery Solutions

Streamlining workflows

Maquet Moduevo Units can accommodate medical supplies for nurse stations, monitors, and ventilation machines. In comparison to fixed headwall solutions, ceiling supply units resolve recurring issues in healthcare environments. By providing space to store equipment and keeping cables off the floor, they simultaneously improve access to patients.

application of VAA in ICU. The ACD contains an electrostatic bacterial and viral filter that replaces the heat and moisture exchange filter. The only available liquid VAA for ACD in Hong Kong at the moment is isoflurane. When liquid isoflurane is given via syringe pump into the ACD, it is saturated into the vaporizer for simultaneous inhalation to the patients through mechanical breaths. When exhaled, the active carbon filter will re-absorb 90% of isoflurane. The remaining 10% will be exhaled via ventilator expiratory cassette to a scavenger system and transported out into the environment.




Fig. 2 Cross-sectional View of the Anaesthetic Conserving Device (ACD, AnaConDa) (Source: Sackey et al., 2004)

To maintain occupational safety and correct titration of the isoflurane, a gas analyzer is connected to the inspiratory port of the ACD to indicate the Minute Alveolar Concentration (MAC) for titration, and to the expiratory cassette of the ventilator to indicate the Expiratory Concentration of isoflurane (EtISO) (Fig. 3). The target of MAC is ~1 and the EtISO is 0.2-0.6. The usual rate of isoflurane infusion to maintain the target of MAC ~1 is 2-7ml/hr. The VAA is directly metabolized in the lung which provides room for liver and kidneys to recover from high dose of IV anti-epileptic drugs and sedation.




Fig. 3 Set-up of the Anaesthetic Conserving Device with ICU Ventilator (Source: Pickworth et al., 2013)

Example of a Case Profile

Our patient who received the first ACD was a 48-year-old male, admitted to ICU due to acute confusion with status epilepticus. Despite aggressive anti-epileptic treatment, including high dose IV sedation, muscle relaxation, thiopentone infusion, IV and oral anti-epileptic drugs, pulse steroid, and seven sessions of plasma exchange, patient remained in epileptic status as shown by EEG, with cerebral swelling shown in MRI after two weeks of treatment. His liver and renal functions deteriorated. No obvious positive microbiology was noted in any screening and lumbar puncture. Autoimmune and neoplastic markers are negative. Blood for genetic mutation (mitochondrial defects) was sent for analysis. The patient was diagnosed with NOSRSE. The case had been discussed in the ICU network among doctors and an anaesthetist was consulted who suggested ACD application on Day 14.

With the application of ACD, limbs twitching of the patient was suspended within a minute, and EEG showed burst suppression within 5 minutes of isoflurane inhalation. The MAC and EtISO was 0.3 and 0.35 respectively with isoflurane given at 4ml/hr. The thiopentone infusion was withheld after 8 hours. Other IV sedation and muscle relaxant were commenced for weaning the next day. The ACD was started on D14 of ICU admission and weaned on D26. All IV sedation had been successfully weaned on D43 and patient (with a tracheostomy and GCS E4VTM2) was discharged from ICU without seizure on D46 to a neurology unit. Unfortunately, the patient developed cardiac arrest four days after ICU discharge in the neurology unit and died. Private lab results of T-tau protein and protein 14-3-3 were high, which suggested prion disease/ transmissible spongiform encephalopathies (Creutzfeldt-Jakob Disease (CJD) / mad cow disease). A post-mortem brain biopsy was required to confirm the diagnosis.

Nursing Care of Patients using Isoflurane Inhalation with ACD

The goals of nursing care are to, 1) maintain optimal oxygenation and prevent overdose of anaesthetic agent, 2) prevent complications related to isoflurane, and 3) prevent leakage of VAA for occupational safety.

- 1) *Maintain optimal oxygenation and prevent overdose of anaesthetic agent*
Assuring adequate minute ventilation can guarantee adequate oxygenation as well as efficient isoflurane delivery. With the mon-

itoring of MAC, EtISO, SpO₂, inO₂ and ABG (Fig. 4), as well as the titration protocol (Fig. 5), optimal isoflurane dosage is monitored and administered.



Fig. 4 EtISO, MAC and inO₂ Values from Gas Analyzer as shown in a Patient Monitoring System




Fig. 5 Volatile Anesthetic Agent Titration Chart (Source: Sedana Medical, 2018)

2) Prevent complications related to isoflurane

Isoflurane may induce malignant hyperthermia with signs of increasing end tidal CO₂, muscle rigidity and high fever >40°C. Regular monitoring of core temperature, ETCO₂, serum calcium level as well as ABG can early detect the development of malignant hyperthermia. Isoflurane also promotes dose-dependent cerebral vasodilation. Therefore, patients with suspected increased intra-cranial pressure should be managed accordingly.

Although isoflurane has a low hemodynamic effect, when it is used in the beginning, due to its rapid action and metabolism, together with the residual effect of IV sedation, patients may develop hypotension. This can be corrected by administering fluid bolus. Once the isoflurane has begun, the IV sedation will need to wean down cautiously per protocol. On the other hand, isoflurane is less hepatotoxic, and it may reduce renal blood flow. Daily monitoring of liver and renal functions, as well as urine output and signs of jaundice, is needed.

3) Prevent leakage of VAA for occupational safety

Isoflurane is easily vaporized under room temperature. There is a risk of isoflurane leakage during the withdrawing of isoflurane into syringe, or connecting and disconnecting

the ACD system with the ventilator circuit and gas analyzer. When withdrawing isoflurane from the supply, one-way valve and special ACD syringe are used to prevent leakage (Fig. 6). A tight connection between the ACD and ventilator circuit is always ensured. When there is a need to disconnect the ACD or ventilator accessories, it is necessary to stop or cap off the isoflurane infusion first. The use of Nafion dryer tubing to connect the ACD to the gas analyzer can evaporate water condensate, and minimize the need to disconnect the gas analyzer for drainage of condensation. Disposal of the unused isoflurane bottle and syringe with the one-way valve and cap can also prevent isoflurane leakage.



Fig. 6 Safety Features of the ACD Syringe (One-way Valves) and Nafion Dryer Tubing (Source: Sedana Medical, 2018)

Conclusion

Volatile anaesthetic agent is efficient in controlling seizures, especially for patients with refractory status epilepticus. The set-up is fast and easy but occupational safety should be ensured. The titration and monitoring are not difficult, protocol and objective data are easy to follow. Different volatile anaesthetic agents have unique end-organ protection effects, all potential complications should be monitored. The use of volatile anaesthetic agents might also be extended to patients in ICU with status asthmaticus and withdrawal syndrome in the near future.

References

- Brophy, G. M., Bell, R., Claassen, J., Alldredge, B., Bleck, T. P., Glauser, T., Laroche, S. M., Riviello, J. J., Jr, Shutter, L., Sperling, M. R., Treiman, D. M., Vespa, P. M., & Neurocritical Care Society Status Epilepticus Guideline Writing Committee (2012). Guidelines for the evaluation and management of status epilepticus. *Neurocritical Care*, 17(1), 3–23. doi:10.1007/s12028-012-9695-z
- Jerath, A., Parotto, M., Wasowicz, M., & Ferguson, N. D. (2016). Volatile anesthetics. Is a new player emerging in critical care sedation? *American Journal of Respiratory and Critical Care Medicine*, 193(11), 1202–1212. doi:10.1164/rccm.201512-2435CP
- Pickworth, T., Jerath, A., DeVine, R., Kherani, N., & Wasowicz, M. (2013). The scavenging of volatile anesthetic agents in the cardiovascular intensive care unit environment: a technical report. *Canadian Journal of Anaesthesia / Journal Canadien D'anesthésie*, 60(1), 38–43. doi:10.1007/s12630-012-9814-5
- Sackey, P. V., Martling, C. R., Granath, F., & Radell, P. J. (2004). Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. *Critical Care Medicine*, 32(11), 2241–2246. doi:10.1097/01.ccm.0000145951.76082.77
- Sedana Medical (2018). *AnaConDa Technical Handbook* (Version 6). Sweden: Sedana Medical AB.
- Stavropoulos, I., Khaw, J. H., & Valentin, A. (2023). Neuromodulation in new-onset refractory status epilepticus. *Frontiers in Neurology*, 14, 1195844. doi:10.3389/fneur.2023.1195844
- Wilder-Smith, E. P., Lim, E. C., Teoh, H. L., Sharma, V. K., Tan, J. J., Chan, B. P., & Ong, B. K. (2005). The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. *Annals of the Academy of Medicine*, 34(7), 417–420.

Bibliography

- Jerath, A., Wong, K., Wasowicz, M., Fowler, T., Steel, A., Grewal, D., Huszti, E., Parotto, M., Zhang, H., Wilcox, M. E., McDonald, B., Overgaard, C., Rao, V., Ferguson, N. D. (2020). Use of inhaled volatile anesthetics for longer term critical care sedation: A pilot randomized controlled trial. *Critical Care Explorations*, 2(11), p0281. doi:10.1097/CCE.0000000000000281
- O'Gara, B., & Talmor, D. (2016). Lung protective properties of the volatile anesthetics. *Intensive Care Medicine*, 42(9), 1487–1489. doi:10.1007/s00134-016-4429-x
- Potievskaya, V. I., Molchanov, I. V., & Krivenko, T. V. (2015). Volatile anesthetics for analgesia and sedation in patients after abdominal surgery in ICU. *Intensive Care Medicine Experimental*, 3(Suppl 1), A329. doi:10.1186/2197-425X-3-S1-A329
- TMH ICU (2021). *Guideline for Using AnaConDa to Administrate Volatile Anesthetic Agent in ICU*. Hong Kong: Tuen Mun Hospital.



Cavilon™

Skin Care Solutions

Finding the optimal solution for your skin integrity needs.

3M™ Cavilon™ Advanced Skin Protectant

Attaches to wet, weepy, damaged skin¹

Provides an effective barrier, which has been shown to reduce the pain of managing IAD¹

Single-use applicator reduces the potential for cross-contamination

Lasts up to 7 days²




Patient with skin damage on Day 2



Patient with improvement noted on Day 4

Moisture-Associated Skin Damage (MASD)



Incontinence-Associated Dermatitis (IAD)



Peristomal Skin Damage



Periwound Skin Damage




Intertriginous Dermatitis (ITD)

Pressure Ulcer/Injury



Medical Adhesive-Related Skin Injury (MARS)



Cavilon Advanced Skin protectant



5051G for Stoma and Fistula



5050G for IAD



3M Hong Kong Limited
38/F, Manhattan Place
23 Wang Tai Road, Kowloon Bay,
Kowloon, Hong Kong
Tel: 2806 6349 Fax: 2234 6044

¹ Brennan, Mary R.; Milne, Catherine T.; Agrell-Kann, Marie; Ekholm, Bruce P. Clinical Evaluation of a Skin Protectant for the Management of Incontinence Associated Dermatitis: An Open-Label, Nonrandomized, Prospective Study. J of Wound, Ostomy & Continence Nursing. 2017, 44(2):172-180.
² 3M data on file, EM-05-01 3924.

THIS IS VENTILATION

The new Evita



draeger.com/evita

Dräger. Technology for Life®

從「我不懂」到「我會學」

凍檸茶

一轉眼，成為護士將近四年。實習時，前輩們都說過許多護理工作的辛酸，因此，我早已對這份工作的壓力抱有心理準備。當時寫了一封「給無力且迷茫的你」的信給自己，好讓自己在工作覺得疲倦無力的時候，提醒自己成為護士的初衷，有力量繼續走下去。至今這封信依然保存在書桌抽屜櫃內。

記得入職前，我們一班小薯前往中央護理部，被詢問我們有興趣工作的部門。當時我選擇了深切治療部，然而深切治療部需要有經驗的護士，那我只好選擇內科，希望打好護理基礎，盼望日後若能轉到深切治療部，可以幫上一點忙。

兩年後，有幸由內科轉到深切治療部，當中體會到兩者最大的分別就是對於病人的照顧。在內科繁重的工作量下，很多護理工作未必能夠全面兼顧。然而，在深切治療部，提供的卻是全人護理。曾經有個病人的女兒前來告訴我，十分感謝我們為母親洗頭，一問之下，原來礙於家居環境和病人身體狀況，他們在家中無法為母親洗頭。對我來說，看到當時女兒撫摸著母親的長髮說：「阿媽，你終於有得洗頭」的這一幕，歷歷在目。深切治療部除了提供重症治療服務，我們都不會忽視如剪指甲、刮鬍子、抹身、口部腔護理等基本照顧。除了因為這些基本照顧可為病人減低感染風險外，也令他們保持尊嚴。這些我們看似簡單的基本護理，對於無法自行完成的病患者來說卻是十分珍貴。

另外，相比起內科，在深切治療部，需要我們與病人及其家屬有更多的溝通。疫情期間，醫院禁止一般探訪，我們護士每日都會致電

家屬講述病人最新情況。記得有一位婆婆，因新冠肺炎入院，需接受高濃度氧氣治療。在照顧婆婆期間，眼見她憂心忡忡，雖然自己仍有大量工作要做，仍是覺得需要了解一下，一問之下，原來婆婆擔心同樣染疫，卻在家中獨自隔離的丈夫。安撫婆婆後，便隨即聯絡她的丈夫和子女，為他們安排多人視像通話。婆婆通話後，彷彿放下心頭大石，面露微笑感謝我們的安排。數天後，婆婆病情惡化，需要插喉和洗血等治療，及後因為多個器官衰竭，家人決定不施行心肺復甦術。婆婆的女兒在恩恤探訪時，哭紅着眼握着我的手多謝我們為他們安排視像通話，令在家中隔離的他們能夠與當時仍然清醒的婆婆見面通話，原來那一次通話，是他們最後一次聽到婆婆的聲音。假如當時只專注醫療護理程序，沒多問一句，了解到婆婆的擔憂，或許會令他們都留有遺憾。

轉到深切治療部的時間，正正是新冠肺炎疫情第四波，當時不少患者情況嚴重，大大增加了深切治療部床位的需求，醫護染疫導致人手短缺，同時令工作量大增。在這個嚴峻的環境，對剛加入深切治療部工作的我來說，卻令我更加了解到自己的不足，當時透過學習、觀察和提問，盡快適應這個既困難又充滿挑戰的新環境。這裏充滿了各種學習的機會，有些病人被診斷出的疾病，我從未聽聞；有些只會在深切治療部提供的治療方法，我第一次嘗試。直至現在，仍有許多需要學習的地方，縱然很不容易，但時刻提醒自己迎難而上，與其只是說「我不懂」，我更希望能夠保持著「我會學」的心態。在未來護士生涯路上，即使沿路崎嶇，途中可能會感到迷茫、沮喪，屆時，拿出那封給自己的信，細閱一下，給自己一點力量繼續前行。不斷學習，勿忘初衷，堅守護士的責任，這是我對自己的承諾。



SUNSHINE MEDICAL SUPPLIES LTD.
E-mail : sales@sunshinemedic.com
Phone: 37058698

NKV-330

Ventilator System

Treasure Every Breath.



Fighting Disease with Electronics



CONFERENCES / EVENTS



American Association of Critical-Care Nurses (AACN) Conference

19 - 23 May 2024

Denver, Colorado, USA

<https://www.emedevents.com/c/medical-conferences-2024/american-association-of-critical-care-nurses-aacn-conference-2024>

ANZICS / ACCCN Intensive Care Annual Scientific Meeting 2024

10 - 12 April 2024

Brisbane Convention and Exhibition Centre, Queensland, Australia

<https://intensivecareasm.com.au/registration/>

39th Annual British Association of Critical Care Nurses (BACCN) Conference

7 - 8 Oct 2024

Aberdeen, UK

<https://www.baccn.org/conference/>

17th World Intensive and Critical Care Congress

16 - 19 Sept 2025

Vancouver, Canada

<https://www.wcicc2025.com/>

USEFUL LINKS

International Nurses Day 2023

Theme: Our Nurses. Our Future.

<https://www.icn.ch/how-we-do-it/campaigns/international-nurses-day>

Australian College of Critical Care Nurses (ACCCN)

<http://www.acccn.com.au/>

Australian and New Zealand Intensive Care Society (ANZICS)

<https://www.anzics.com.au/>

British Association of Critical Care Nurses (BACCN)

<https://baccn.org/>

Canadian Association of Critical Care Nurses (CACCN)

<https://www.caccn.ca/>

European federation of Critical Care Nursing association (EfCCNa)

<http://www.efccna.org/>

Hong Kong Academy of Nursing (HKAN)

<http://www.hkan.hk>

Hong Kong Society of Critical Care Medicine (HKSCCM)

<http://www.hkscm.org/>

World Federation of Critical Care Nurses (WFCCN)

<https://wfccn.org/>

Major Schools of Nursing in Hong Kong

HKU: <https://nursing.hku.hk/>

CUHK: <http://www.nur.cuhk.edu.hk/>

PolyU: <https://sn.polyu.edu.hk/en/home/>

Critical Care Nursing Journals

AACN Advanced Critical Care

<http://acc.aacnjournals.org/>

American Journal of Critical Care

<http://ajcc.aacnjournals.org/>

Critical Care

<https://ccforum.biomedcentral.com/>

Heart and Lung

<http://www.heartandlung.org/>

Intensive and Critical Care Nursing

<https://www.journals.elsevier.com/intensive-and-critical-care-nursing>



HKACCN Board of Directors 2021-2023

CHAN Yui Fung	LAO Wing Yung, Benny	TSE Hau Heung, Ruby
CHAN Yuk Ching	LAW Chiu Shan, Jenny	WONG Yi Ting, Tracy
CHIU Yeung Lin	LEUNG Fung Yee	WONG Yiu Chung, Paul
CHOO Tat Ming	LI Yuen, Tracy	WU Chung Ming, Timothy
LAI Wing Yan, Vivien	POON Yuk Chun	YU Hin Lung, Wayne



香港危重病學護士協會有限公司
Hong Kong Association of Critical Care Nurses Limited

Baxter

PrisMax

ACUTE CARE SYSTEM

TOGETHER, WE'RE DEDICATED
TO ADVANCE WHAT'S POSSIBLE IN CRITICAL CARE



INTEGRATION OF ECCO₂R



ADJUNCTIVE THERAPY
FOR SEPSIS MANAGEMENT



24/7 DELIVERY OF TPE



For safe and proper use, please refer to the Operator's Manual or Instructions for use on the products mentioned herein.

The Prismax control unit is intended for: Continuous Renal Replacement Therapy (CRRT) for patients with acute renal failure and/or overload.
Therapeutic Plasma Exchange (TPE) for patients with diseases where removal of plasma components is indicated.
Extracorporeal CO₂ Removal (ECCO₂R) for patients with conditions where extracorporeal elimination of carbon dioxide is indicated.

CE 0123

Baxter Healthcare Ltd.

Suites 2701-03, Oxford House, Taikoo Place,
979 King's Road, Island East, Hong Kong
Tel: (852) 2807 8500 Fax: (852) 2807 8596


HK-AT21-220003 09/22

Now with one proven solution


From proven prevention to effective treatment



Proprietary Deep Defense® Technology -
Strength and flexibility, in perfect balance



Mepilex® Border Sacrum



Mepilex® Border Heel

Find out more at www.molnlycke.com
Email: hkproductenquiry@molnlycke.com

